Evidence map›Paper›PMID 33074557›Full record

Trial reportDiabetes, obesity & metabolism2021

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial.

Linong Ji, Xiaolin Dong, Yiming Li, Yufeng Li, Soo Lim, Ming Liu, Zu Ning, Søren Rasmussen, Trine Vang Skjøth, Guoyue Yuan and 1 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03061214. Cited by 60 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 15 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03061214 phase3completed

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes. A 30-week Randomised, Double-blind, Double-dummy, Active-controlled, Parallel-group, Multi-centre and Multi-national Trial

Ran2017Enrolled868Registered outcomes74Posted comparisons4ConditionsDiabetes, Diabetes Mellitus, Type 2ArmsSemaglutide 0.5 mg, Semaglutide 1.0 mg, Semaglutide placebo 0.5 mg, Semaglutide placebo 1.0 mg, Sitagliptin
Open the trial in the graph
3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 15 syntheses or guidelines pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 3 countries.

Linong JiPeking University People's Hospital No. 11, Beijing, China.ORCID 0000-0003-1305-1598
Xiaolin DongJinan Central Hospital, Affiliated to Shandong University No. 105, Jinan, China.
Yiming LiShanghai Huashan Hospital, Affiliated to Fudan University No. 12, Shanghai, China.
Yufeng LiBeijing Pinggu Hospital No. 59, Beijing, China.
Soo LimDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.ORCID 0000-0002-4137-1671
Ming LiuGeneral Hospital of Tianjin Medical University No. 154, Tianjin, China.
Zu NingNovo Nordisk (China) Pharmaceuticals Co., Ltd, Beijing, China.
Søren RasmussenNovo Nordisk A/S, Søborg, Denmark.
Trine Vang SkjøthNovo Nordisk A/S, Søborg, Denmark.
Guoyue YuanThe Affiliated Hospital of Jiangsu University No. 438, Zhenjiang, China.
Freddy G EliaschewitzCPClin/DASA Centro de Pesquisas Clínicas, São Paulo, Brazil.
Novo Nordisk (Denmark) · DKBeijing Anding Hospital · CNFudan University · CNJiangsu University · CNPeking University · CNSeoul National University Bundang Hospital · KRShandong University · CNTianjin Medical University General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo evaluate the efficacy and safety of once-weekly subcutaneous semaglutide, a glucagon-like peptide-1 (GLP-1) analogue, versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes (T2D) in a multiregional clinical trial. MATERIALS AND

methodsIn the 30-week, randomized, double-blind, double-dummy, active comparator SUSTAIN China trial, 868 adults with T2D inadequately controlled on metformin (HbA1c 7.0%-10.5%) were randomized to receive once-weekly semaglutide 0.5 mg (n = 288), semaglutide 1.0 mg (n = 290) or once-daily sitagliptin 100 mg (n = 290). The primary and confirmatory secondary endpoints were change from baseline to week 30 in HbA

resultsThe trial enrolled ~70% (605/868) of the patients in China, and the remaining patients from four other countries, including the Republic of Korea. Both doses of semaglutide were superior to sitagliptin in reducing HbA

conclusionsOnce-weekly semaglutide was superior to sitagliptin in improving glycaemic control and reducing body weight in patients with T2D inadequately controlled on metformin. The safety and tolerability profiles were consistent with those of semaglutide and other GLP-1 RAs. Semaglutide is an effective once-weekly treatment option for the Chinese population.

Indexed as

Diabetes Mellitus, Type 2MetforminAdultChinaDouble-Blind MethodDrug Therapy, CombinationGlucagon-Like PeptidesGlycated HemoglobinHumansHypoglycemic AgentsRepublic of KoreaSemaglutideSitagliptin PhosphateTreatment OutcomeGlucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsMetforminSemaglutideSitagliptin PhosphateGLP-1 analogue, glycaemic control, incretin therapy, phase III study, randomized trial, type 2 diabetes

Identifiers

PMID33074557
PMCPMC7839591
OpenAlexW3093123473

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.